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Abstract 
Introduction. The study aims to investigate the change in the burden of disease and the 
microbiological characteristics of Invasive Meningococcal Disease (IMD) in Puglia in 
comparison with overall incidence from 1994 through 2014. 
Methods. Data are gathered in the frame of the National Surveillance System coordi-
nated by the National Reference Laboratory (NRL) of the Istituto Superiore di Sanità.
Results. In Puglia, from 1994 through 2014, the average incidence of IMD was 0.2 per 
100 000 inhabitants, below the national average value (0.33). IMD cases tended to be 
older than the other cases reported in Italy (median age 19 vs 16). The case-fatality rate 
was 20.4% in Puglia vs 13.3% in Italy. Serogroups B and C were most frequently identi-
fied. Serogroups C and Y presented a fairly clonal pattern, whereas serogroup B was 
genetically rather heterogeneous. 
Conclusion. Surveillance systems are critical in monitoring any change in the epidemiol-
ogy of IMD. 
INTRODUCTION
Invasive Meningococcal Disease (IMD) due to the 
human pathogen Neisseria meningitidis is a severe dis-
ease. This infection has different clinical consequenc-
es: meningitis, septicemia, arthritis, pneumonia, and 
pericarditis; moreover, long-term sequelae including 
learning difficulties, hearing impairment, neurologic, 
behavioral and motor deficits. Cases occur worldwide; 
although the majority of cases are sporadic, small out-
breaks may occur [1].The majority of cases are reported 
in the African meningitis belt, the sub-Saharan region 
where recurrent epidemic are mainly due to N. menin-
gitidis of serogroup A [2]. In Europe, IMD cases due to 
serogroup B, C, Y and more rarely W, have been report-
ed (http://ecdc.europa.eu/en/publications/Publications/
AER-VPD-IBD-2014.pdf).
In Italy, a third of bacterial meningitis and sepsis is 
caused by N. meningitidis (www.iss.it/mabi/), and the 
serogroup B remains the leading cause of IMD in the 
pediatric and adolescent age groups. In our Country, 
the National Surveillance System of Bacterial Menin-
gitis was established in 1994; in 2007, the national sur-
veillance was extended to all invasive bacterial diseases, 
including those due to N. meningitidis. 
Routine immunization for meningococcal serogroup 
C disease has recommended at the national level since 
its introduction in 2005. However, vaccination policies 
in Italy show territorial heterogeneity [3]. Vaccination 
meningococcal C coverage against N. meningitidis at the 
24th month of age is very high but needs to be improved 
through specific strategies. New conjugate vaccines 
against serogroups A, C, Y, and W are required to offer 
greater protection; in fact, serogroup Y increased in re-
cent years, and rare cases of W have been also reported 
(www.iss.it/mabi/). Moreover, the Bexsero vaccine (the 
novel multicomponent MenB vaccine based on immu-
nogenic proteins), which is now available, has shown, in 
the pre-licensure study [4], a predicted strain coverage 
for Italy of 87% (IC 70-93).
Puglia is one of the largest and most populated regions 
of southern Italy (4085 millions of inhabitants; www.
istat.it/it/popolazione). It was one of the first Region that 
introduced universal vaccination with the MCC conju-
gate vaccine. In particular, the vaccination is offered to 
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all children aged 15 months. Vaccination with the con-
jugate vaccine against ACYW is also offered to children 
around 12 years old, as well as to people considered at 
risk (i.e., a co-payment regiment is provided for travelers 
to endemic countries). The MenB vaccination is offered 
free of charge to the 2014 cohort of infants, with a vac-
cination schedule of three doses administered at 3-4 and 
6 months of age, and a booster dose at 15th months of age 
(DRG n. 958 del 20/5/2014 www.sanita.puglia.it/portal/
pls/portal/docs/1/2097490.PDF). The vaccine coverage 
of MCC in Puglia, for the birth cohorts 2004-2011, in-
creased from 48% in 2006 to 83% in 2013 (www.epicen-
tro.iss.it/temi/vaccinazioni/pdf/Istruttoria%20MENIN-
GOCOCCO%20B.pdf; www.sincon.it/dettaglio_media.
php?id=76). Lower coverage rates for MCC or quadri-
valent ACYW were reported in 11-12 years-old children, 
ranging from 48% in 2006 (birth cohort of 1995) to less 
than 50% in 2013 (birth cohort of 2002), with a peak in 
the 1998 (70%) birth cohort. The Regional Surveillance 
System for IMD in Puglia has been implemented start-
ing from 2013. Moreover, the Regional Reference Labo-
ratory provides molecular test to ascertain the etiology of 
the disease, thus improving the surveillance system.
The study aims to investigate the change in the bur-
den of disease and the microbiological characteristics 
of IMD cases in Puglia in comparison with overall inci-
dence from 1994 through 2014. 
MATERIALS AND METHODS
Surveillance system
In Italy, all cases of S. pneumoniae, N. meningitidis, and 
H. influenzae are notified in the frame of the National 
Surveillance System of Bacterial Invasive Diseases at 
the ISS. Confirmed cases are reported to regional and 
national authorities through the Local Health Units. 
The 2008 EU case definition (revised in 2012), based 
on clinical and laboratory criteria, is used for surveil-
lance purposes. 
For each IMD case, epidemiological information and 
samples are sent to ISS [5]. Data are managed using a 
dedicated database. Microbiological analysis, including 
serogroup confirmation and typing data, are performed 
routinely on all reported cases and the strains are stored 
at -80 °C. Molecular testing is also performed by the 
Regional Reference Centre. Surveillance reports are 
published periodically (www.iss.it/mabi/).
Microbiological analyses
Serogroup was confirmed by slide agglutination with 
commercial antisera (Remel Europe, Ltd, UK) or by 
multiplex PCR [6]. Susceptibility to penicillin G, rifam-
picin, ciprofloxacin and ceftriaxone was determined by 
E-test Method (bioMérieux SA, France) on Mueller-
Hinton agar (Oxoid) supplemented with 5% of sheep 
blood. The breakpoints were those recommended by 
the European Committee on Antimicrobial Suscepti-
bility Testing − EUCAST version 5.0, January 1, 2015 
(www.eucast.org/).
Molecular typing
Chromosomal DNA was extracted by using the 
QIAamp DNA minikit (Qiagen, Hilden, Germany), ac-
cording to the manufacturer’s instructions. Multilocus 
sequence typing (MLST), PorA and FetA typing were 
defined as described in http://neisseria.org/. The fine-
type was as follows: capsular group: porA (P1). VR1, 
VR2: fetA VR: ST (cc). MLST data were analysed by 
eBURST, version 3, (http://eburst.mlst.net), [7]. eBurst 
analysis was set up referring to the most stringent set-
ting of six identical out of the seven housekeeping gene 
alleles.
Statistical analysis
The data were analysed using EpiInfo (version 3.4.5. 
July 30, 2013). Odds ratios (OR), 95% confidence in-
terval were obtained to measure the strength of the as-
sociation of variables of interest. Statistical differences 
were tested using standard tests.
RESULTS 
Over twenty years, from 1994 to 2014, 174 IMD 
cases, out of 4263 nationally reported (www.iss.mabi) 
occurred in Puglia. The average incidence in the period 
was 0.2 cases per 100 000 inhabitants, lower than the 
national incidence rate (0.33 per 100 000 inhabitants). 
However, the regional incidence trend was consistent 
with the national one, with two peaks in 2000 and 2005, 
respectively, (Figure 1). Differently from what reported 
for the rest of Italy, an increase of cases was detected 
in Puglia in 2013, with an incidence of 0.46 cases per 
100 000 inhabitants, higher than the overall incidence 
(0.27 per 100 000 inhabitants), (Figure 1) maybe to the 
implementation of the regional surveillance system. All 
the 19 cases occurred in 2013 were sporadic, except 
for 3 cases of unknown serogroup, with a geo-temporal 
clustering pattern, occurring from 20th to 27th of Febru-
ary 2013 in a small geographic area (around 20 km) of 
the Region.
Consistently with the seasonal pattern observed in 
Italy in the period, also in Puglia most cases (44.8%) 
occurred during the January-March trimester. 
In Puglia, patients tended to be older (median age 
19 years vs 16 years in the rest of Italy), ranging from 
1 month to 87 years with respect to cases reported in 
the rest of Italy. During the twenty years study period, 
the 22% of cases occurred in the age group from 5 to 
14 years. The percentages in the other age groups (< 1, 
1-4, 15-24, 25-44, 45-64, and > 64) were 7.7%, 12%, 
15.5%, 16.1%, 16.7% and 10%, respectively.
However, since 2013, half of the IMD cases occurred 
among patients aged ≥ 45 years old (52%). Moreover, 
in the entire period, the IMD incidence among infants 
less than 1 year of age was higher than the overall popu-
lation (1.95 per 100 000 inhabitants). The incidences 
in the other age groups (1-4, 5-14, 15-24, 25-44, 45-64, 
and > 64) were 0.7, 0.46, 0.28, 0.12, 0.12 and 0.1 per 
100 000 inhabitants, respectively.
Not statistically significant difference was found be-
tween females (84) and males (90).
As in the rest of Italy, meningitis was the main clinical 
picture (62% of cases), followed by sepsis and meningi-
tis plus sepsis. Of note, in the years 2013-2014, the fre-
quency of meningitis in Puglia was significantly higher 
than in Italy (85% vs 43%, p < 0.05).
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The outcome of the disease, available for 54 out of 
174 cases, was fatal for 11 patients (OR1.67 in com-
parison to the overall Italian data). From 1994 through 
2014, the case-fatality rate in Puglia was 20.4% vs 13.3% 
reported in Italy.
The serogroup was defined for 40 out of 174 invasive 
meningococcal cases. The serogroup distribution was as 
follows: 22 (55%) serogroup B, 13 (32.5%) serogroup 
C, 4 (10%) serogroup Y, and 1 (2.5%) serogroup W. The 
proportion of serogroup B and C was consistent with 
the national data, where these serogroups represented 
59% and 33% of the cases, respectively. Three out of 
the 4 serogroup Y meningococci were isolated in 2013, 
in 2 teen-agers and 1adult; no epidemiological link was 
found among them.
All the analysed meningococci were susceptible to 
rifampicin, ciprofloxacin, and ceftriaxone. Moreover, 
47% showed a decreased susceptibility to penicillin G 
(MIC50 and MIC90 were 0.064 and 0.125mg/L, respec-
tively).
Molecular analyses
Molecular analysis, started in 2010, was performed 
on 16 out of 19 isolates/clinical samples received by the 
NRL (Table 1). Among serogroup B, ST-41/44 complex 
(cc41/44) was identified as the major clonal complex 
(71.4%). The remaining isolates belonged to ST-461 
complex (cc461) and to a new sequence type ST-11119 
(clonal complex unknown), corresponding to a new 
MLST profile occurred in 2014.
Four different sequence types (STs) were found in 
the cc41/44: ST-1403 (2 isolates), ST-3615, ST-41 and 
ST-414. The sequence types ST-41 and ST-414 were 
single-locus variants (SLV) at the eBurst analysis. Six 
different finetypes was identified of which B: P1.7-2,4: 
F1-5: ST-1403 (cc41/44) was found among two unre-
lated isolates.
The ST-11 complex (cc11) characterized serogroup C 
meningococci. Four out of them showed the same fine-
type C: P1.5-1,10-8: F3-6: ST-11 (cc11); two of these 
strains were isolated in January 2014 in the same city 
(S. Giovanni Rotondo).
Three serogroup Y meningococci, isolated in 2013, be-
longed to ST-23 complex (cc23), as already reported for 
the majority of serogroup Y isolated in the country, [8]. 
CONCLUSIONS
The national surveillance system for invasive menin-
gococcal disease provides a better understanding of the 
dimensions of the problem and of the impact of immu-
nization strategies on the incidence of IMD. 
In Puglia, the increasing incidence of IMD reported 
since 2013 can be in part due to the improvement of the 
efficiency of the surveillance system (i.e., case detec-
tion) due to the use of more sensitive diagnostic tests. 
Prior to 2005, serogroup C meningococci were re-
sponsible for most of the IMD; since that year, the 
epidemiology of IMD in Italy has changed, showing a 
decrease of serogroup C and a relative increase of se-
rogroup B. The decline appears to be associated with 
the introduction and widespread use of the conjugate 
serogroup C vaccine in the country. The development 
of new vaccines against invasive meningococcal disease 
provides, in fact, important opportunities for reducing 
the burden of disease. Therefore, it will be extremely in-
teresting to monitor the dynamic of invasive meningo-
coccal disease over time, in order to evaluate the impact 
of the immunization programs.
The Puglia Region, one of the largest and most popu-
lated regions in the south of Italy, was one of the first to 
introduce the universal vaccination with the conjugate 
MCC vaccine. However, no major differences between 
regional and national data were found, with regard to 
the incidence of the disease and the main circulating 
serogroups (B and C). Some minor differences con-
cerned the median age of infected patients, which was 
higher in Puglia (19 vs 16 year old in the rest of the 
country), and the case-fatality rate, which was about 1.5 
time higher than the rest of Italy. We cannot exclude the 
higher case-fatality be due to more efficient data collec-
tion in the region, allowing for a more accurate count of 
real number of deaths.
The higher median age of the patients with IMD 
observed in Puglia could be partially explained by age-
dependent nasopharyngeal carriage and/or to an indi-
rect effect due to MCC vaccination [9]. However, the 
determinants of such difference remain undefined. The 
decreasing susceptibility to penicillin together with the 
decrease of the incidence rate is a phenomenon al-
ready described [9, 10]. The genetic characteristics of 
the circulating isolates in Puglia show the presence of 
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Figure 1
Trend of Invasive Meningococcal Disease incidence from 1994 through 2014 in Italy and in Puglia.
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the major clonal complexes identified in the rest of the 
country, except for one case with a new Sequence Type. 
The serogroups C and Y presented a fairly clonal pat-
tern, whereas serogroup B isolates were rather geneti-
cally heterogeneous.
Before concluding, some limits of the analysis need to 
be mentioned. Firsty, IMD cases are likely to be under-
estimated, since only laboratory confirmed cases are re-
ported. Secondly, because of the lack of molecular data 
prior to the 2010, the circulation of the main hyperviru-
lent meningococcal clonal complexes in Puglia and in 
the rest of the country cannot be compared. 
In conclusion, a surveillance system including mo-
lecular diagnosis and typing of the circulating menin-
gococci is essential to monitor any changes in the epi-
demiological pattern of invasive meningococcal disease 
due to immunization strategies adopted locally and na-
tionally. Our data support the need for an harmonized 
vaccination schedule for MenB and Men ACYW conju-
gate vaccine through the country. 
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Table 1
Microbiological and epidemiological data of 16 invasive meningococcal diseases cases, 2010-2014
Finetype [porA (P1). VR1,VR2: fetA VR: ST (cc)] Year Month City Clinical picture Age 
(years)
B: P1.7-35,4: F1-5: ST-3615 (cc41/44) 2010 January S. Giovanni Rotondo meningitis 7
B: P1.7-2,4: F1-5: ST-41 (cc41/44) 2010 May S. Giovanni Rotondo sepsis 6
B: P1.18,25: F1-84: ST-414 (cc41/44) 2010 December Foggia meningitis 8
B: P1.7-2,4: F1-5: ST-1403 (cc41/44) 2012 August Foggia meningitis + sepsis 17
B: P1.19-2,13-1: F3-9: ST-461 (cc41/44) 2013 June Bari meningitis 29
B: P1.7-2,13-2: F1-5: ST-11119 (UNK) 2014 February Bari meningitis 3
B: P1.7-2,4: F1-5: ST-1403 (cc41/44) 2014 August S. Giovanni Rotondo meningitis 60
C: P1.5-1,10-8: F3-6: ST-11 (cc11) 2013 October Bari meningitis 13
C: P1.5-1,10-8: F3-6: ST-11 (cc11) 2014 January S. Giovanni Rotondo sepsis 0
C: P1.5-1,10-8: F3-6: ST-11 (cc11) 2014 January S. Giovanni Rotondo meningitis 51
C: P1.5-2,nd: F1-6: ST-nd (cc11) 2014 April Taranto sepsis 63
C: P1.5-1,10-8: F3-6: ST-11 (cc11) 2014 May Bari meningitis 18
Y: P1.5-2,10-21: F2-13: ST-23 (cc23) 2013 March Brindisi meningitis 53
Y: P1.5-2,10-2: F2-13: ST-9253 (cc23) 2013 April Foggia meningitis + sepsis 18
Y: P1.5-2,10-2: F2-13: ST-023 (cc23) 2013 June S. Giovanni Rotondo meningitis 12
W: P1.18-1,3: F4-1: ST-3189 (cc22) 2011 March Foggia meningitis 14
UNK: not known
nd: not determined
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